{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T17:44:09Z","timestamp":1790790249533,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":944,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Cardiac amyloidosis (CA) is an under-diagnosed cause of heart failure (HF) and has a worse prognosis than other forms of HF. The frequency of death or rehospitalization following discharge for acute heart failure (AHF) in CA (relative to other causes) has not been documented. The study aims to compare hospital readmission and death rates 90 days after discharge for AHF in patients with vs. without CA and to identify risk factors associated with these events in each group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>Patients with HF and CA (HF + CA+) were recruited from the ICREX cohort, after screening of their medical records. The cases were matched 1:5 by sex and age with control HF patients without CA (HF + CA\u2212). There were 27 HF + CA + and 135 HF + CA\u2212 patients from the ICREX cohort included in the study. Relative to the HF + CA\u2212 group, HF + CA+ patients had a higher heart rate (P = 0.002) and N-terminal prohormone of brain natriuretic peptide levels (P &amp;lt; 0.001) and lower blood pressure (P &amp;lt; 0.001), weight, and body mass index values (P &amp;lt; 0.001) on discharge. Ninety days after discharge, the HF + CA+ group displayed a higher death rate, a higher all-cause hospital readmission rate, and a higher hospital readmission rate for AHF. Death and hospital readmissions occurred sooner after discharge in the HF + CA+ group than in the HF + CA\u2212 group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The presence of CA in patients with HF was associated with a three-fold greater risk of death and a two-fold greater risk of all-cause hospital readmission 90 days after discharge. These findings emphasize the importance of close, active management of patients with CA and AHF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14337","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T03:48:13Z","timestamp":1681357693000},"page":"2042-2050","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Patients with Cardiac Amyloidosis are at a Greater Risk of Mortality and Hospital Readmission After Acute Heart Failure"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0418-3110","authenticated-orcid":false,"given":"Emmanuelle","family":"Berthelot","sequence":"first","affiliation":[{"name":"Universit\u00e9 Paris Sud , Paris ,","place":["France"]},{"name":"Department of Cardiology, AP-HP, Hopital Bic\u00eatre , 78, rue du g\u00e9n\u00e9ral Leclerc, Le Kremlin Bic\u00eatre, 94043, Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaury","family":"Broussier","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, AP-HP, Henri-Mondor\/Emile-Roux Hospitals , Paris ,","place":["France"]},{"name":"Univsit\u00e9 Paris Est Cr\u00e9teil, INSERM, IMRB , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Hittinger","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart Failure and Amyloidosis Unit, Referral Center For Cardiac Amyloidosis, Universit\u00e9 Paris Est, AP-HP, Henri-Mondor\/Albert-Chenevier Hospitals , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Donadio","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, AP-HP, H\u00f4pital Charles Foix and Sorbonne Universit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Rovani","sequence":"additional","affiliation":[{"name":"Hopital Priv\u00e9 Paul D\u00e9gine , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Salengro","sequence":"additional","affiliation":[{"name":"Centre Hospitalier de Villeneuve St Georges , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Megbemado","sequence":"additional","affiliation":[{"name":"H\u00f4pital Sainte Camille , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Godreuil","sequence":"additional","affiliation":[{"name":"H\u00f4pital d'Instruction des Arm\u00e9es B\u00e9gin , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Belmin","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, AP-HP, H\u00f4pital Charles Foix and Sorbonne Universit\u00e9 , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Philippe","family":"David","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, AP-HP, Henri-Mondor\/Emile-Roux Hospitals , Paris ,","place":["France"]},{"name":"Univsit\u00e9 Paris Est Cr\u00e9teil, INSERM, IMRB , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastien","family":"Genet","sequence":"additional","affiliation":[{"name":"BioStatistics Unit, AP-HP , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart Failure and Amyloidosis Unit, Referral Center For Cardiac Amyloidosis, Universit\u00e9 Paris Est, AP-HP, Henri-Mondor\/Albert-Chenevier Hospitals , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"FINC-94 Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"key":"2026012114105556500_ehf214337-bib-0001","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","article-title":"ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC","volume":"33","author":"Authors\/Task Force Members","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012114105556500_ehf214337-bib-0002","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"2026012114105556500_ehf214337-bib-0003","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1056\/NEJMsa0803563","article-title":"Rehospitalizations among patients in the Medicare Fee-for-Service Program","volume":"360","author":"Jencks","year":"2009","journal-title":"N Engl J Med"},{"key":"2026012114105556500_ehf214337-bib-0004","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1016\/j.mayocp.2019.05.027","article-title":"Readmissions among patients admitted with acute decompensated heart failure based on income quartiles","volume":"94","author":"Patil","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2026012114105556500_ehf214337-bib-0005","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.amjcard.2015.07.018","article-title":"Comparison of risk of re-hospitalization, all-cause mortality, and medical care resource utilization in patients with heart failure and preserved versus reduced ejection fraction","volume":"116","author":"Nichols","year":"2015","journal-title":"Am J Cardiol"},{"key":"2026012114105556500_ehf214337-bib-0006","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12877-021-02210-0","article-title":"Good performance in the management of acute heart failure in cardiogeriatric departments: the ICREX-94 experience","volume":"21","author":"Berthelot","year":"2021","journal-title":"BMC Geriatr"},{"key":"2026012114105556500_ehf214337-bib-0007","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.jchf.2018.03.006","article-title":"Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction","volume":"6","author":"Tsao","year":"2018","journal-title":"JACC Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0008","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012114105556500_ehf214337-bib-0009","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/ejhf.2504","article-title":"Unmasking the prevalence of amyloid cardiomyopathy in the real world: results from Phase 2 of the Ac-tive study, an Italian nationwide survey","volume":"24","author":"Merlo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0010","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012114105556500_ehf214337-bib-0011","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1002\/ejhf.2616","article-title":"Value of the Hfa-Peff and H2Fpef scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis","volume":"24","author":"Tomasoni","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0012","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1002\/ejhf.2658","article-title":"Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy","volume":"24","author":"Maestro-Benedicto","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0013","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archinte.165.12.1425","article-title":"Senile systemic amyloidosis presenting with heart failure: a comparison with light chain\u2013associated amyloidosis","volume":"165","author":"Ng","year":"2005","journal-title":"Arch Intern Med"},{"key":"2026012114105556500_ehf214337-bib-0014","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0015","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0016","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/13506129.2016.1221815","article-title":"Identification of prognostic markers in transthyretin and AL cardiac amyloidosis*","volume":"23","author":"Damy","year":"2016","journal-title":"Amyloid."},{"key":"2026012114105556500_ehf214337-bib-0017","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1016\/j.jacc.2021.09.858","article-title":"Assessing cardiac amyloidosis subtypes by unsupervised phenotype clustering analysis","volume":"78","author":"Bonnefous","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"2026012114105556500_ehf214337-bib-0018","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/0895-4356(96)00025-X","article-title":"Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis","volume":"49","author":"Sun","year":"1996","journal-title":"J Clin Epidemiol"},{"key":"2026012114105556500_ehf214337-bib-0019","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0895-4356(00)00314-0","article-title":"Adjusting for multiple testing\u2014when and how?","volume":"54","author":"Bender","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"2026012114105556500_ehf214337-bib-0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/13506129.2021.2013193","article-title":"Describing mode of death in three major cardiac amyloidosis subtypes to improve management and survival","volume":"29","author":"Kharoubi","year":"2022","journal-title":"Amyloid"},{"key":"2026012114105556500_ehf214337-bib-0021","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012114105556500_ehf214337-bib-0022","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1002\/ehf2.13443","article-title":"Progress and challenges in the treatment of cardiac amyloidosis: a review of the literature","volume":"8","author":"Adam","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0023","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ejhf.2027","article-title":"Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study","volume":"23","author":"Damy","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0024","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.jaccao.2020.10.007","article-title":"Amyloidosis and 30-day outcomes among patients with heart failure","volume":"2","author":"Arora","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026012114105556500_ehf214337-bib-0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/ejhf.682","article-title":"Precipitating factors and 90-day outcome of acute heart failure: a report from the intercontinental Great registry","volume":"19","author":"Arrigo","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0026","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.ahj.2008.04.030","article-title":"Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)","volume":"156","author":"O'Connor","year":"2008","journal-title":"Am Heart J"},{"key":"2026012114105556500_ehf214337-bib-0027","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"2026012114105556500_ehf214337-bib-0028","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of Empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-reduced trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"key":"2026012114105556500_ehf214337-bib-0029","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (transthyretin) stabilizers are associated with improved survival in patients with TTR cardiac amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10163519","article-title":"Diagnosis and management of heart failure in elderly patients from hospital admission to discharge: position paper","volume":"10","author":"Damy","year":"2021","journal-title":"J Clin Med"},{"key":"2026012114105556500_ehf214337-bib-0031","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008335","article-title":"Trends in 30- and 90-day readmission rates for heart failure","volume":"14","author":"Khan","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0032","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ijcard.2017.01.153","article-title":"The prevalence of frailty in heart failure: a systematic review and meta-analysis","volume":"236","author":"Denfeld","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026012114105556500_ehf214337-bib-0033","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.jamda.2018.06.009","article-title":"Frailty and clinical outcomes in heart failure: a systematic review and meta-analysis","volume":"19","author":"Zhang","year":"2018","journal-title":"J Am Med Dir Assoc"},{"key":"2026012114105556500_ehf214337-bib-0034","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ijcard.2020.04.043","article-title":"Heart failure, frailty, and pre-frailty: a systematic review and meta-analysis of observational studies","volume":"316","author":"Marengoni","year":"2020","journal-title":"Int J Cardiol"},{"key":"2026012114105556500_ehf214337-bib-0035","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.nut.2009.12.007","article-title":"Evidence that albumin is not a suitable marker of body composition-related nutritional status in elderly patients","volume":"27","author":"Bouillanne","year":"2011","journal-title":"Nutrition"},{"key":"2026012114105556500_ehf214337-bib-0036","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.008105","article-title":"Prevalence and prognostic significance of frailty among patients with transthyretin amyloidosis cardiomyopathy","volume":"14","author":"Fine","year":"2021","journal-title":"Circ Heart Fail"},{"key":"2026012114105556500_ehf214337-bib-0037","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10153415","article-title":"Frailty in wild-type transthyretin cardiac amyloidosis: the tip of the iceberg","volume":"10","author":"Broussier","year":"2021","journal-title":"J Clin Med"},{"key":"2026012114105556500_ehf214337-bib-0038","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jaccao.2020.06.007","article-title":"Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis","volume":"2","author":"Cheng","year":"2020","journal-title":"JACC CardioOncology"},{"key":"2026012114105556500_ehf214337-bib-0039","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jchf.2020.12.005","article-title":"The impact of patients with cardiac amyloidosis in HFpEF trials","volume":"9","author":"Oghina","year":"2021","journal-title":"JACC Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/2042\/65017939\/eschf_10_3_2042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/10\/3\/2042\/65017939\/eschf_10_3_2042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T19:12:11Z","timestamp":1769022731000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/10\/3\/2042\/8304727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,4,13]]},"published-print":{"date-parts":[[2023,6,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14337","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"2022-08-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}